Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF) [Phase 1]

View source ↗

Summary

This update notes the completion of a Phase 1 study evaluating vismodegib in combination with ruxolitinib for intermediate- or high-risk myelofibrosis, focusing…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Ruxolitinib (Jakafi) (ruxolitinib)
• Vismodegib (Erivedge) (vismodegib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Myelofibrosis | Phase 1 | Status: COMPLETED